SOURCE: Industrial Info Resources

April 15, 2009 07:00 ET

Genzyme Takes Bayer to Relieve Headache of Entering Seattle Biotech Hub, an Industrial Info News Alert

SUGAR LAND, TX--(Marketwire - April 15, 2009) - Researched by Industrial Info Resources (Sugar Land, Texas) -- Genzyme (NASDAQ:GENZ) (Cambridge, Massachusetts), arguably the world's largest maker of drugs for genetic diseases, has entered into a strategic alliance with Bayer AG (PINKSHEETS:BAYRY) (Leverkusen, Germany), by obtaining three of its oncology product lines: Campath, Fludara and Leukine. One drug in particular, Leukine, will allow Genzyme to make its first foray into the Seattle Biotech Market.

For details, view the entire article by subscribing to Industrial Info's Premium Industry News at, or browse other breaking industrial news stories at

Industrial Info Resources (IIR) is a marketing information service specializing in industrial process, energy and financial related markets with products and services ranging from industry news, analytics, forecasting, plant and project databases, as well as multimedia services. For more information send inquiries to or visit us at

Related News Articles

Washington University Invests $235 Million to Construct Translational BioMedical Institute

Tufts Unveils Most Recent Addition to Nation's Plan for 13 Regional Biosafety Laboratories

Massachusetts Leads 2Q09 Capital Investment in New England with $1.2 Billion in Project Starts

Contact Information

  • Contact:
    Joe Govreau